Levetiracetam Solution
Product Images NDC 16714-358

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 16714-358). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Levetiracetam Fig1)

Figure 1 (Levetiracetam Fig1)
The text is a figure caption showing responder rates in Study 1, with percentages of 39.6% and 37.1% for two groups labeled as "Ll" and "Pcabo", respectively. There is also a note indicating that the Pcabo group was statistically significant compared to placebo.*
FDA Label Image

Figure 2 (Levetiracetam Fig2)

Figure 2 (Levetiracetam Fig2)
The text describes a figure called "Responder Rate" with results displayed as percentages for a study called "Study 2" in a period called "Period A". There are three percentages given as results, 35.2%, 208%, and 63%, and a comparison is made with a drug called Leveraceam and a placebo. The text appears to be part of a scientific or medical report.*
FDA Label Image

Figure 3 (Levetiracetam Fig3)

Figure 3 (Levetiracetam Fig3)
FDA Label Image

Figure 4 (Levetiracetam Fig4)

Figure 4 (Levetiracetam Fig4)
The text describes a figure showing the responder rate (>50% reduction from baseline) in Study 4. The figure shows percentage values ranging from 0% to 44.6% with a sample size of 97 patients who received the placebo. There is also a note stating that the result was statistically significant versus placebo.*
FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
This is a figure showing the responder rate for patients aged 1 month to <4 years in Study 5. The responder rate is a 50% reduction from baseline. The placebo group (N=51) had a responder rate of 19.6%, while the levetiracetam group (N=58) had a responder rate of 43.5%, which is statistically significant versus placebo.*
FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
The text describes a figure (Figure 6) presenting the percentage of patients who responded (>50% reduction from baseline) to a treatment for PGTC seizure frequency per week in Study 7. The figure shows that 72.2% of patients who received Levetiracetam responded to the treatment compared to only 45.2% of patients who received placebo (N=84 and N=79 respectively). The text also specifies that the difference is statistically significant.*
FDA Label Image

Package Label-principal Display Panel (100 mg/mL (473 mL Bottle))

Package Label-principal Display Panel (100 mg/mL (473 mL Bottle))
FDA Label Image

Chemical Structure (Levetiracetam Str)

Chemical Structure (Levetiracetam Str)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.